Friday, June 4, 2010

Biosimilars are in demand from 1/3 of Pharma Market

According to a recent article at San Francisco City & Press, up to 1/3 of the Pharma market can have demand for biologics.

The opportunity presented to the biosimilars market with the article stating that “numerous biologic therapies with total revenues of $37B will have lost patent protection by 2017, promising considerable opportunity in biosimilars (government-approved new versions of branded biopharmaceutical products following patent expiration),”

Harry Glorikian, managing partner of Scientia Advisors, stated, “With the market for biologic* drugs growing much faster than that of drugs based on chemical compounds, pharmaceutical, biotechnology, generic drug and contract manufacturing companies are repositioning and forming new alliances in order to succeed in a rapidly changing landscape.”

Read the full article here.

Share this article with your social network, just click below to share now!

No comments :

Post a Comment